Innovent Biologics, Inc.
Innovent Biologics, Inc.
Explore linked clinical trials.10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-09-15 | NCT07061535 | |
| A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-08-25 | NCT07412262 | |
| Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Body Weight, Endometrial Hyperplasia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, atypical endometrial hyperplasia, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, nutritional disorder, obesity disorder, overnutrition, uterine disorder | Not yet recruiting | Phase 2 | 2026-08-24 | NCT07781150 | |
| Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) | Body Weight, Body Weight Changes, Insulin Resistance, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, diabetes mellitus, endocrine system disorder, glucose intolerance, glucose metabolism disease, hyperglycemia, hyperinsulinism, metabolic disease, prediabetes syndrome | Not yet recruiting | Phase 4 | 2026-06-17 | NCT07654062 | |
| Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer | Pancreatic Cancer Metastatic | Not yet recruiting | Phase 1 / Phase 2 | 2026-01-15 | NCT07342725 | |
| A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation | KRAS G12C Lung Cancer | Not yet recruiting | Phase 2 | 2025-04-20 | NCT06936644 | |
| HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2024-12-03 | NCT03869034 | |
| A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, female reproductive system disorder, female reproductive system neoplasm, neoplasm, vaginal cancer, vaginal disorder, vulva cancer, vulvar disease | Recruiting | Phase 2 | 2024-11-21 | NCT06292689 | |
| Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population | acute coronary syndrome, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Not yet recruiting | Not applicable | 2023-10-24 | NCT06096909 | |
| Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Not yet recruiting | Phase 4 | 2023-06-06 | NCT05843292 |